AINOSTICS
AINOSTICS is a UK-based award-winning artificial intelligence company specializing in medical diagnostics for neurological disorders. Founded on over two decades of research, it commercializes AI-driven technology that automates and personalizes diagnosis of tissue-modifying diseases using multi-modal clinical imaging and non-imaging data. Its flagship product, BR[AI]N®, is FDA Breakthrough Device designated for predicting Alzheimer's disease conversion from MRI scans. The company focuses on improving clinical workflows, diagnosis, prognosis, and therapy monitoring for diseases like Alzheimer's, Multiple Sclerosis, Stroke, and brain tumors. It has secured over $6 million in funding, established clinical and pharma partnerships, and is expanding global regulatory approvals and deployments, positioning itself as a leader in AI-powered neurodiagnostics and clinical trial analytics.
AINOSTICS
AINOSTICS is a UK-based award-winning artificial intelligence company specializing in medical diagnostics for neurological disorders. Founded on over two decades of research, it commercializes AI-driven technology that automates and personalizes diagnosis of tissue-modifying diseases using multi-modal clinical imaging and non-imaging data. Its flagship product, BR[AI]N®, is FDA Breakthrough Device designated for predicting Alzheimer's disease conversion from MRI scans. The company focuses on improving clinical workflows, diagnosis, prognosis, and therapy monitoring for diseases like Alzheimer's, Multiple Sclerosis, Stroke, and brain tumors. It has secured over $6 million in funding, established clinical and pharma partnerships, and is expanding global regulatory approvals and deployments, positioning itself as a leader in AI-powered neurodiagnostics and clinical trial analytics.